Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-723 in Patients With Solid Tumors
NCT04685226Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Sep 2020
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zurlectrectinib in solid tumor, central nervous system tumor, sponsored by InnoCare Pharma. Started Sep 2020; status: recruiting.
02
Drugs
zurlectrectinib
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT04685226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685226.